Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

Masahiko Tsujii, Sunao Kawano, Raymond N. Dubois

Research output: Contribution to journalArticle

1271 Citations (Scopus)

Abstract

Recent epidemiologic studies have shown a 40-50% reduction in mortality from colorectal cancer in individuals who take nonsteroidal antiinflammatory drugs on a regular basis compared with those not taking these agents. One property shared by all of these drugs is their ability to inhibit cyclooxygenase (COX), a key enzyme in the conversion of arachidonic acid tn prostaglandins. Two isoforms of cox have been characterized, COX-1 and COX- 2. COX-2 is expressed at high levels in intestinal tumors in humans and rodents. Human colon cancer cells (Caco-2) were permanently transfected with a COX-2 expression vector or the identical vector lacking the COX-2 insert. The Caco-2 cells, which constitutively expressed COX-2, acquired increased invasiveness compared with the parental Caco-2 cells or the vector transfected control cells. Biochemical changes associated with this phenotypic change included activation of metalloproteinase-2 and increased rna levels for the membrane-type metalloproteinase. Increased invasiveness and prostaglandin production were reversed by treatment with sulindac sulfide, a known COX inhibitor. These studies demonstrate that constitutive expression of COX-2 can lead to phenotypic changes that alter the metastatic potential of colorectal cancer cells.

Original languageEnglish (US)
Pages (from-to)3336-3340
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume94
Issue number7
DOIs
StatePublished - Apr 1 1997
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Colonic Neoplasms
Caco-2 Cells
Metalloproteases
Prostaglandins
Colorectal Neoplasms
Cyclooxygenase 1
Cyclooxygenase Inhibitors
Prostaglandin-Endoperoxide Synthases
Arachidonic Acid
Pharmaceutical Preparations
Epidemiologic Studies
Rodentia
Protein Isoforms
Anti-Inflammatory Agents
RNA
Membranes
Mortality
Enzymes
Neoplasms

Keywords

  • invasion
  • metalloproteinase
  • prostaglandins
  • sulindac sulfide)

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. / Tsujii, Masahiko; Kawano, Sunao; Dubois, Raymond N.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, No. 7, 01.04.1997, p. 3336-3340.

Research output: Contribution to journalArticle

@article{81f1461adb084329860eb03c382688f8,
title = "Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential",
abstract = "Recent epidemiologic studies have shown a 40-50{\%} reduction in mortality from colorectal cancer in individuals who take nonsteroidal antiinflammatory drugs on a regular basis compared with those not taking these agents. One property shared by all of these drugs is their ability to inhibit cyclooxygenase (COX), a key enzyme in the conversion of arachidonic acid tn prostaglandins. Two isoforms of cox have been characterized, COX-1 and COX- 2. COX-2 is expressed at high levels in intestinal tumors in humans and rodents. Human colon cancer cells (Caco-2) were permanently transfected with a COX-2 expression vector or the identical vector lacking the COX-2 insert. The Caco-2 cells, which constitutively expressed COX-2, acquired increased invasiveness compared with the parental Caco-2 cells or the vector transfected control cells. Biochemical changes associated with this phenotypic change included activation of metalloproteinase-2 and increased rna levels for the membrane-type metalloproteinase. Increased invasiveness and prostaglandin production were reversed by treatment with sulindac sulfide, a known COX inhibitor. These studies demonstrate that constitutive expression of COX-2 can lead to phenotypic changes that alter the metastatic potential of colorectal cancer cells.",
keywords = "invasion, metalloproteinase, prostaglandins, sulindac sulfide)",
author = "Masahiko Tsujii and Sunao Kawano and Dubois, {Raymond N.}",
year = "1997",
month = "4",
day = "1",
doi = "10.1073/pnas.94.7.3336",
language = "English (US)",
volume = "94",
pages = "3336--3340",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "7",

}

TY - JOUR

T1 - Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

AU - Tsujii, Masahiko

AU - Kawano, Sunao

AU - Dubois, Raymond N.

PY - 1997/4/1

Y1 - 1997/4/1

N2 - Recent epidemiologic studies have shown a 40-50% reduction in mortality from colorectal cancer in individuals who take nonsteroidal antiinflammatory drugs on a regular basis compared with those not taking these agents. One property shared by all of these drugs is their ability to inhibit cyclooxygenase (COX), a key enzyme in the conversion of arachidonic acid tn prostaglandins. Two isoforms of cox have been characterized, COX-1 and COX- 2. COX-2 is expressed at high levels in intestinal tumors in humans and rodents. Human colon cancer cells (Caco-2) were permanently transfected with a COX-2 expression vector or the identical vector lacking the COX-2 insert. The Caco-2 cells, which constitutively expressed COX-2, acquired increased invasiveness compared with the parental Caco-2 cells or the vector transfected control cells. Biochemical changes associated with this phenotypic change included activation of metalloproteinase-2 and increased rna levels for the membrane-type metalloproteinase. Increased invasiveness and prostaglandin production were reversed by treatment with sulindac sulfide, a known COX inhibitor. These studies demonstrate that constitutive expression of COX-2 can lead to phenotypic changes that alter the metastatic potential of colorectal cancer cells.

AB - Recent epidemiologic studies have shown a 40-50% reduction in mortality from colorectal cancer in individuals who take nonsteroidal antiinflammatory drugs on a regular basis compared with those not taking these agents. One property shared by all of these drugs is their ability to inhibit cyclooxygenase (COX), a key enzyme in the conversion of arachidonic acid tn prostaglandins. Two isoforms of cox have been characterized, COX-1 and COX- 2. COX-2 is expressed at high levels in intestinal tumors in humans and rodents. Human colon cancer cells (Caco-2) were permanently transfected with a COX-2 expression vector or the identical vector lacking the COX-2 insert. The Caco-2 cells, which constitutively expressed COX-2, acquired increased invasiveness compared with the parental Caco-2 cells or the vector transfected control cells. Biochemical changes associated with this phenotypic change included activation of metalloproteinase-2 and increased rna levels for the membrane-type metalloproteinase. Increased invasiveness and prostaglandin production were reversed by treatment with sulindac sulfide, a known COX inhibitor. These studies demonstrate that constitutive expression of COX-2 can lead to phenotypic changes that alter the metastatic potential of colorectal cancer cells.

KW - invasion

KW - metalloproteinase

KW - prostaglandins

KW - sulindac sulfide)

UR - http://www.scopus.com/inward/record.url?scp=0030952695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030952695&partnerID=8YFLogxK

U2 - 10.1073/pnas.94.7.3336

DO - 10.1073/pnas.94.7.3336

M3 - Article

C2 - 9096394

AN - SCOPUS:0030952695

VL - 94

SP - 3336

EP - 3340

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 7

ER -